PRINCETON, N.J., June 21, 2018 /PRNewswire/ -- Taiho Oncology, Inc. and Servier today announced clinical data from the pivotal Phase III trial (TAGS) evaluating LONSURF® (trifluridine and tipiracil, TAS-102) plus
Growth Capitalist (https://growthcapitalist.com/2018/06/taiho-oncology-and-servier-present-data-on-lonsurf-trifluridine-and-tipiracil-at-esmo-20th-world-congress-on-gastrointestinal-cancer-2018/)
PRINCETON, N.J., June 21, 2018 /PRNewswire/ -- Taiho Oncology, Inc. and Servier today announced clinical data from the pivotal Phase III trial (TAGS) evaluating LONSURF® (trifluridine and tipiracil, TAS-102) plus